Revance Therapeutics ( (RVNC) ) has issued an update.
On February 6, 2025, Revance Therapeutics finalized a merger with Crown Laboratories, resulting in the delisting of Revance’s common stock from NASDAQ and significant changes to the company’s equity awards and convertible notes. This merger, initiated by a tender offer at $3.65 per share, culminated in Crown Laboratories acquiring approximately 82% of Revance’s outstanding shares, with Revance continuing as the surviving corporation. The transaction led to a restructuring of Revance’s board and executive positions, with Crown’s executives assuming leadership roles.
More about Revance Therapeutics
YTD Price Performance: 19.28%
Average Trading Volume: 3,209,000
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $381M
Find detailed analytics on RVNC stock on TipRanks’ Stock Analysis page.